Opus Genetics (IRD) Other Non-Current Liabilities (2010 - 2026)

Opus Genetics' (IRD) quarterly Other Non-Current Liabilities came in at $77.3 million in Q1 2026, up 197.67% on a QoQ basis from $26.0 million in Q4 2025.

Opus Genetics (IRD) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends

Opus Genetics (IRD) has 14 years of Other Non-Current Liabilities data on file, last reported at $77.3 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $77.3 million in Q1 2026; TTM through Mar 2026 was $77.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $26.0 million, changed N/A from the prior year.
  • Other Non-Current Liabilities for Q1 2026 stood at $77.3 million, up from $26.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for IRD reached as high as $77.3 million in Q1 2026 and fell as low as $25000.0 in Q4 2023.
  • Historically, Other Non-Current Liabilities has averaged $20.7 million across 3 years, with a median of $93000.0 in 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Opus Genetics 3.27 Mn -56.73 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 77.35 Mn
Dec 31, 2025 25.99 Mn
Dec 31, 2023 25,000.00
Sep 30, 2023 93,000.00
Jun 30, 2023 80,000.00
Dec 31, 2020 27.96 Mn
Sep 30, 2019 123,872.00
Jun 30, 2019 366,732.00
Mar 31, 2019 794,215.00
Dec 31, 2018 2.31 Mn
Sep 30, 2018 4.10 Mn
Jun 30, 2018 3.39 Mn
Mar 31, 2018 4.49 Mn
Dec 31, 2017 7.85 Mn
Sep 30, 2017 6.68 Mn
Jun 30, 2017 9.80 Mn
Mar 31, 2017 16.23 Mn
Dec 31, 2016 1.57 Mn
Sep 30, 2016 3.16 Mn
Jun 30, 2016 2.34 Mn